Reference
- Zaja, F., Vianelli, N., Sperotto, A., Patriarca, F., Tani, M., Mann, L., et al. (2003) "Anti-CD20 for chronic lymphocytic leukemia-associated autoimmune diseases", Leuk. Lymphoma, 44, 1951 — 1955.
- Hegde, UP., Wilson, W.H., White, T. and Cheson, B.D. (2002) "Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia", Blood, 100, 2260–2262.
- Shvidel, L., Klepfish A. and Berrebi, A. (2001) "Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma", Am. J. Hematol., 67, 213–214.
- Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S., et al. (2002) "Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia", Leukemia, 16, 2092–2095.
- Keating, M.J., O'Brien, S. and Albitar, M. (2002) "Emerging information on the use of rituximab in chronic lymphocytic leukemia", Semin. Oncol., 29s2, 70–74.
- Eisenberg, R. (2003) "SLE-Rituximab in lupus", Arthritis Res. Ther., 5, 157 — 159.
- Stasi, R., Pagano, A., Stipa, E. and Amadori, S. (2001) "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenia purpura", Blood, 98, 952 — 957.